Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
Lamb CA, Sebastian S, Kent AJ, Segal JP, Gonzalez HA, Brookes MJ, Mehta SJ, Subramanian S, Bhala N, Hicks LC, Conley TE, Patel KV, Walker GJ, Kennedy NA; PREPARE-IBD Study Group. Lamb CA, et al. Aliment Pharmacol Ther. 2021 Jun;53(11):1236-1240. doi: 10.1111/apt.16349. Aliment Pharmacol Ther. 2021. PMID: 33961708 Free PMC article.
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
Saifuddin A, Kent AJ, Mehta SJ, Hicks LC, Gonzalez HA, Segal JP, Brookes MJ, Subramanian S, Bhala N, Conley TE, Patel KV; PREPARE-IBD Collaborators; Lamb CA, Walker GJ, Kennedy NA, Sebastian S. Saifuddin A, et al. Aliment Pharmacol Ther. 2022 Nov;56(10):1460-1474. doi: 10.1111/apt.17223. Epub 2022 Oct 5. Aliment Pharmacol Ther. 2022. PMID: 36196569 Free PMC article.
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA; PROTECT-ASUC Study Group. Sebastian S, et al. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):271-281. doi: 10.1016/S2468-1253(21)00016-9. Epub 2021 Feb 2. Lancet Gastroenterol Hepatol. 2021. PMID: 33545083 Free PMC article.
Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study.
Sebastian S, Patel KV, Segal JP, Subramanian S, Conley TE, Gonzalez HA, Kent AJ, Saifuddin A, Hicks L, Mehta S, Bhala N, Brookes MJ, Lamb CA, Kennedy NA; PROTECT ASUC collaborators; Walker GJ. Sebastian S, et al. BMJ Open Gastroenterol. 2022 Jan;9(1):e000763. doi: 10.1136/bmjgast-2021-000763. BMJ Open Gastroenterol. 2022. PMID: 35101886 Free PMC article.
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic.
Kennedy NA, Hansen R, Younge L, Mawdsley J, Beattie RM, Din S, Lamb CA, Smith PJ, Selinger C, Limdi J, Iqbal TH, Lobo A, Cooney R, Brain O, Gaya DR, Murray C, Pollok R, Kent A, Raine T, Bhala N, Lindsay JO, Irving PM, Lees CW, Sebastian S. Kennedy NA, et al. Frontline Gastroenterol. 2020 Jun 16;11(5):343-350. doi: 10.1136/flgastro-2020-101520. eCollection 2020. Frontline Gastroenterol. 2020. PMID: 32874484 Free PMC article.
The Paddington International Virtual Chromoendoscopy Score in ulcerative colitis exhibits very good inter-rater agreement after computerized module training: a multicenter study across academic and community practice (with video).
Trivedi PJ, Kiesslich R, Hodson J, Bhala N, Boulton RA, Cooney R, Gui X, Iqbal T, Li KK, Mumtaz S, Pathmakanthan S, Quraishi MN, Sagar VM, Shah A, Sharma N, Siau K, Smith S, Ward S, Widlak MM, Bisschops R, Ghosh S, Iacucci M. Trivedi PJ, et al. Gastrointest Endosc. 2018 Jul;88(1):95-106.e2. doi: 10.1016/j.gie.2018.02.044. Epub 2018 Mar 13. Gastrointest Endosc. 2018. PMID: 29548940
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore DJ, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Goldenberg SD, Williams HRT. Mullish BH, et al. Gut. 2018 Nov;67(11):1920-1941. doi: 10.1136/gutjnl-2018-316818. Epub 2018 Aug 28. Gut. 2018. PMID: 30154172 Free article.
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines.
Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, Moore D, Colville A, Bhala N, Iqbal TH, Settle C, Kontkowski G, Hart AL, Hawkey PM, Williams HR, Goldenberg SD. Mullish BH, et al. J Hosp Infect. 2018 Sep;100 Suppl 1:S1-S31. doi: 10.1016/j.jhin.2018.07.037. J Hosp Infect. 2018. PMID: 30173851 Free article. No abstract available.
94 results